General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 131: What is the drug of choice for the treatment of malignant hyperthermia?

A. Dantrolene sodium (Correct Answer)
B. Potassium chloride
C. Atropine
D. Corticosteroids

Explanation: **Explanation:** **Malignant Hyperthermia (MH)** is a life-threatening pharmacogenetic disorder triggered by volatile anesthetics (e.g., Halothane) and depolarizing muscle relaxants (e.g., Succinylcholine). It involves a mutation in the **Ryanodine Receptor (RyR1)**, leading to massive calcium release from the sarcoplasmic reticulum, resulting in muscle rigidity, hypermetabolism, and severe hyperthermia. **Why Dantrolene Sodium is the Correct Answer:** Dantrolene is a direct-acting skeletal muscle relaxant. It acts as an antagonist at the **RyR1 receptor**, effectively blocking the release of calcium from the sarcoplasmic reticulum. By restoring calcium homeostasis, it halts the hypermetabolic process, making it the specific life-saving antidote for MH. **Why Other Options are Incorrect:** * **Potassium Chloride:** MH often causes hyperkalemia due to rhabdomyolysis; administering potassium would be dangerous and potentially fatal. * **Atropine:** This is an anticholinergic used to treat bradycardia or organophosphate poisoning. It has no role in calcium signaling in skeletal muscle. * **Corticosteroids:** While used to reduce inflammation or cerebral edema, they do not address the underlying pathophysiology of MH. **High-Yield Clinical Pearls for NEET-PG:** * **Early Sign:** The earliest clinical sign of MH is an **increase in end-tidal CO2 (ETCO2)**, followed by masseter muscle rigidity. * **Safe Agents:** For patients with a history of MH, safe alternatives include IV Propofol, Ketamine, and Ester/Amide local anesthetics. * **Dantrolene Formulation:** Modern formulations like *Ryanodex* require less diluent, allowing for faster administration. * **Other Uses of Dantrolene:** It is also used in the management of Neuroleptic Malignant Syndrome (NMS) and spasticity associated with upper motor neuron lesions.

Question 132: 6-Mercaptopurine (6-MP), frequently used in drug regimens for neoplastic disease, is metabolized by xanthine oxidase. Major dose reductions are advised in patients who are being treated with which of the following drugs that inhibit xanthine oxidase?

A. Cimetidine
B. Sulfinpyrazone
C. Allopurinol (Correct Answer)
D. Indomethacin

Explanation: The correct answer is **Allopurinol**. **Mechanism of Interaction:** 6-Mercaptopurine (6-MP) is a purine analog used in the treatment of leukemia [3]. Its primary metabolic pathway involves oxidation by the enzyme **xanthine oxidase (XO)** into inactive 6-thiouric acid [1]. **Allopurinol** is a potent inhibitor of xanthine oxidase (clinically used for gout) [2]. When administered concurrently, Allopurinol prevents the degradation of 6-MP, leading to toxic systemic levels of the chemotherapy drug [1]. This results in severe, life-threatening bone marrow suppression. Therefore, if a patient requires both drugs, the dose of 6-MP must be reduced to **25–33% (1/3rd to 1/4th)** of the original dose. **Analysis of Incorrect Options:** * **A. Cimetidine:** An H2-receptor antagonist and a known microsomal enzyme (Cytochrome P450) inhibitor, but it does not inhibit xanthine oxidase. * **B. Sulfinpyrazone:** A uricosuric agent that inhibits the reabsorption of uric acid in the proximal tubule; it does not inhibit the synthesis of uric acid via xanthine oxidase . * **D. Indomethacin:** A non-steroidal anti-inflammatory drug (NSAID) used for acute gouty arthritis; it inhibits cyclooxygenase (COX) but has no effect on purine metabolism. **NEET-PG High-Yield Pearls:** * **Azathioprine**, a prodrug of 6-MP, follows the same metabolic rule. Its dose must also be reduced when given with Allopurinol or Febuxostat. * **Febuxostat** is a newer, non-purine selective inhibitor of xanthine oxidase that carries the same interaction risk. * **Thiopurine Methyltransferase (TPMT):** This is the other major enzyme that metabolizes 6-MP. Genetic deficiency of TPMT also leads to 6-MP toxicity. * **Drug of Choice:** Allopurinol is the drug of choice for preventing **Tumor Lysis Syndrome** during chemotherapy [1].

Question 133: Which of the following statements is NOT true regarding mycophenolate mofetil?

A. It is a prodrug of mycophenolic acid.
B. It can be used concurrently with a calcineurin inhibitor and a glucocorticoid.
C. It cannot be used concurrently with azathioprine.
D. It is nephrotoxic. (Correct Answer)

Explanation: **Explanation:** **Mycophenolate Mofetil (MMF)** is a potent immunosuppressant widely used in transplant medicine. The correct answer is **D** because MMF is notably **not nephrotoxic**, which distinguishes it from calcineurin inhibitors (CNIs) like Cyclosporine and Tacrolimus. 1. **Why Option D is the correct answer:** MMF’s primary advantage in renal transplantation is its lack of nephrotoxicity. Its dose-limiting toxicities are primarily **gastrointestinal** (nausea, vomiting, diarrhea) and **hematological** (leukopenia, anemia). Because it does not damage the kidneys, it is often used to allow for a reduction in the dose of nephrotoxic CNIs. 2. **Analysis of Incorrect Options:** * **Option A:** MMF is indeed a **prodrug** that is rapidly hydrolyzed in the liver to its active metabolite, **mycophenolic acid (MPA)**. * **Option B:** In clinical practice, the "Triple Drug Regimen" for maintenance immunosuppression typically consists of a **CNI** (Tacrolimus/Cyclosporine), an **antimetabolite** (MMF), and a **glucocorticoid** (Prednisolone). * **Option C:** MMF and Azathioprine are both antimetabolites that inhibit purine synthesis. Using them together increases the risk of severe bone marrow suppression without added benefit; therefore, they are **not** used concurrently. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Potent, reversible, non-competitive inhibitor of **Inosine Monophosphate Dehydrogenase (IMPDH)**. This inhibits the *de novo* pathway of guanosine nucleotide synthesis. * **Selectivity:** T and B lymphocytes are highly dependent on the *de novo* pathway (unlike other cells which use the salvage pathway), making MMF a selective lymphocyte inhibitor. * **Teratogenicity:** MMF is associated with "Mycophenolate Embryopathy" (ear and facial abnormalities) and is contraindicated in pregnancy.

Question 134: What is the term for a pharmaceutical agent specifically developed to treat a rare medical condition affecting fewer than 200,000 people?

A. Orphan Drug (Correct Answer)
B. Primary Drug
C. Rare Drug
D. Pioneer Drug

Explanation: ### Explanation **Correct Option: A. Orphan Drug** An **Orphan Drug** is a pharmaceutical agent intended for the diagnosis, prevention, or treatment of a rare disease. In the United States (under the Orphan Drug Act), a rare disease is defined as one affecting **fewer than 200,000 people**. Because the market for such drugs is small, pharmaceutical companies are often reluctant to develop them due to high costs and low potential for profit. To encourage development, governments provide incentives such as tax credits, simplified marketing authorization, and extended patent exclusivity (usually 7 years). **Analysis of Incorrect Options:** * **B. Primary Drug:** This is not a standard pharmacological classification. It may be confused with "Essential Medicines," which are drugs that satisfy the priority healthcare needs of a population. * **C. Rare Drug:** While these drugs treat rare diseases, "Rare Drug" is not the formal regulatory or pharmacological term used in medical literature or examinations. * **D. Pioneer Drug:** Also known as a "Brand-name" or "Innovator" drug, this refers to the first version of a drug produced by a manufacturer and protected by a patent, regardless of the prevalence of the disease it treats. **High-Yield Clinical Pearls for NEET-PG:** * **Examples of Orphan Drugs:** Digoxin immune Fab (for digitalis toxicity), Fomepizole (for methanol poisoning), Thalidomide (for leprosy/multiple myeloma), and Liothyronine (for myxedema coma). * **Indian Context:** The prevalence threshold for rare diseases in India is generally considered 1 in 5,000 people or less. * **Key Incentive:** The primary hurdle for orphan drugs is the **"lack of commercial viability,"** which is offset by government-granted **market exclusivity**.

Question 135: According to the Food and Drug Administration (FDA) lactation categories, what does category 'S' refer to?

A. Safe for nursing infant; medication usually compatible with breastfeeding.
B. Safety in nursing infants unknown; inadequate literature available.
C. Potential for significant effects on nursing infants; medication should be given with caution. (Correct Answer)
D. Not safe for nursing infants; medication contraindicated or requires cessation of breastfeeding.

Explanation: ### Explanation The classification of drugs during lactation is essential for ensuring neonatal safety while maintaining maternal health. While the FDA has transitioned toward the **Pregnancy and Lactation Labeling Rule (PLLR)**, the traditional letter-based categories remain a high-yield topic for competitive exams like NEET-PG. **1. Why Option C is Correct:** **Category S (Significant)** indicates that the drug has the potential to cause significant adverse effects in nursing infants. These medications are not strictly contraindicated, but they must be administered with **extreme caution**. The clinician must weigh the maternal benefit against the potential neonatal risk, often monitoring the infant closely for specific toxicity. **2. Analysis of Incorrect Options:** * **Option A (Category L - Low Risk/Safe):** Refers to drugs that are considered compatible with breastfeeding (e.g., Paracetamol, Ibuprofen). There is no evidence of adverse effects in infants. * **Option B (Category U - Unknown):** This is used when there is inadequate literature or no controlled studies available regarding the drug's excretion into breast milk or its effect on the infant. * **Option D (Category X - Contraindicated):** This refers to drugs that are known to be harmful to the nursing infant (e.g., Amiodarone, Cytotoxic drugs, Ergotamine). In such cases, the drug should be avoided, or breastfeeding must be discontinued. **3. Clinical Pearls & High-Yield Facts:** * **M/P Ratio:** The Milk-to-Plasma ratio helps determine drug excretion. A ratio **< 1.0** suggests low concentration in milk. * **Molecular Weight:** Drugs with low molecular weight (<200 Da) cross into milk more easily. * **Ion Trapping:** Since breast milk is slightly more acidic (pH ~7.2) than plasma (pH 7.4), **basic drugs** (like alkaloids) tend to accumulate in milk due to ion trapping. * **Rule of Thumb:** Advise mothers to take medications immediately **after** breastfeeding to ensure the lowest possible drug concentration during the next feed.

Question 136: Which of the following is NOT a function of Prostaglandin E1?

A. Erectile dysfunction
B. Treatment of patent ductus arteriosus
C. Induction of puberty (Correct Answer)
D. Patent ductus arteriosus

Explanation: **Explanation:** Prostaglandin E1 (PGE1), also known as **Alprostadil**, is a potent vasodilator and smooth muscle relaxant [1]. The correct answer is **Induction of puberty**, as PGE1 has no physiological or pharmacological role in the onset of puberty, which is governed by the hypothalamic-pituitary-gonadal axis (GnRH, LH, and FSH). **Analysis of Options:** * **Erectile Dysfunction (A):** Alprostadil is used as a second-line treatment for ED [1]. It can be administered via intracavernosal injection or intraurethral suppository to induce vasodilation and relax the trabecular smooth muscle of the corpora cavernosa. * **Patent Ductus Arteriosus (B & D):** These options refer to the clinical management of PDA. PGE1 is used to **maintain patency** of the ductus arteriosus in neonates with cyanotic heart disease (e.g., Transposition of Great Arteries) until surgery can be performed [1], [2]. Conversely, NSAIDs like Indomethacin or Ibuprofen are used to *close* a PDA. (Note: Option D likely refers to the "maintenance" of the PDA). **High-Yield Clinical Pearls for NEET-PG:** * **Misoprostol (PGE1 analog):** Used for NSAID-induced peptic ulcers and medical abortion (combined with Mifepristone) [1]. * **Dinoprostone (PGE2):** Used for cervical ripening and induction of labor [1]. * **Latanoprost (PGF2̑):** First-line treatment for Open-Angle Glaucoma (increases uveoscleral outflow) [1]. * **Epoprostenol (PGI2):** Used in Pulmonary Arterial Hypertension [1]. * **Side Effect:** A common side effect of Alprostadil injection is priapism (prolonged erection).

Question 137: Therapeutic drug monitoring is not indicated for which of the following medications?

A. Propranolol (Correct Answer)
B. Phenytoin
C. Piroxicam
D. Prazosin

Explanation: **Explanation:** Therapeutic Drug Monitoring (TDM) is indicated for drugs with a narrow therapeutic index, high inter-individual pharmacokinetic variability, or when clinical toxicity is difficult to distinguish from the disease itself. **Why Propranolol is the correct answer:** TDM is generally **not indicated** for drugs where the clinical effect (pharmacodynamic response) can be easily measured using simple physiological parameters. For **Propranolol** (a beta-blocker), the therapeutic effect and toxicity can be accurately monitored by measuring the **heart rate and blood pressure**. Therefore, plasma concentration levels do not provide additional clinical utility. **Analysis of other options:** * **Phenytoin:** This is a classic indication for TDM. It exhibits **zero-order (saturation) kinetics** even at therapeutic doses, meaning small dose increases can lead to disproportionate rises in plasma levels and toxicity. * **Piroxicam:** While not as commonly monitored as Phenytoin, NSAIDs with very long half-lives or those used in specific toxicological contexts are sometimes evaluated; however, in the context of this specific question (often a repeat from older medical exams), **Prazosin** and **Propranolol** are the primary distractors. * **Prazosin:** Similar to Propranolol, Prazosin's effect is easily monitored via blood pressure (checking for first-dose hypotension). However, in most standardized NEET-PG patterns, Propranolol is the definitive "textbook" example of a drug monitored by physiological response rather than TDM. **Clinical Pearls for NEET-PG:** * **Indications for TDM:** Lithium, Digoxin, Aminoglycosides (Gentamicin), Theophylline, Cyclosporine, and Antiepileptics (Phenytoin, Carbamazepine). * **TDM is NOT needed when:** 1. The drug has a wide therapeutic window. 2. The effect is easily measurable (e.g., BP for Antihypertensives, INR for Warfarin, Blood sugar for Insulin). 3. The drug is an irreversible inhibitor (e.g., Aspirin). 4. The drug is a "hit and run" drug (e.g., Reserpine, Guanethidine).

Question 138: What specific information is collected during Phase IV clinical trials?

A. Drug efficacy
B. Drug potency
C. Drug toxicity (Correct Answer)
D. Other possible uses of the drug

Explanation: **Explanation:** **Phase IV Clinical Trials**, also known as **Post-Marketing Surveillance**, are conducted after a drug has been approved by regulatory authorities (like the FDA or CDSCO) and is available to the general public. **Why "Drug Toxicity" is the correct answer:** The primary objective of Phase IV is to monitor the **long-term safety** and detect **rare or delayed adverse drug reactions (ADRs)** that may not have surfaced during Phase I-III trials. Since pre-approval trials involve a limited number of highly selected patients (usually <3,000), they lack the statistical power to detect rare toxicities (e.g., 1 in 10,000). Phase IV observes the drug’s performance in the "real world" across diverse populations, making it the definitive stage for identifying chronic toxicity and idiosyncratic reactions. **Analysis of Incorrect Options:** * **A. Drug Efficacy:** This is primarily established during **Phase II** (initial efficacy) and **Phase III** (confirmatory efficacy in large groups). * **B. Drug Potency:** This is a pharmacodynamic property usually determined during **pre-clinical animal studies** and **Phase I** trials. * **D. Other possible uses:** While new indications may be discovered incidentally, the *specific regulatory purpose* of Phase IV is safety monitoring. Exploring new uses usually requires starting new Phase II/III trials for that specific indication. **High-Yield NEET-PG Pearls:** * **Phase 0:** Microdosing studies (Human microdosing) to study pharmacokinetics. * **Phase I:** Safety and tolerability in **healthy volunteers** (Exception: Anti-cancer drugs). * **Phase II:** Smallest group of **patients**; determines the therapeutic dose range. * **Phase III:** Large-scale, multicentric, randomized controlled trials (RCTs); the "Gold Standard." * **Black Box Warning:** Often added to a drug's label based on Phase IV toxicity data.

Question 139: Therapeutic drug monitoring is indicated for which of the following drugs, except?

A. Warfarin
B. Phenytoin
C. Gentamicin
D. Cycloserine (Correct Answer)

Explanation: **Explanation:** Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug concentrations in the blood to maintain a therapeutic range. It is indicated for drugs with a **narrow therapeutic index**, high inter-individual pharmacokinetic variability, or a lack of easily measurable physiological markers of effect. **Why Cycloserine is the correct answer:** Cycloserine is a second-line antitubercular drug. While it has significant neurotoxicity, its dosage is typically adjusted based on clinical response and the emergence of side effects rather than routine serum concentration monitoring. In clinical practice, TDM is not standard for cycloserine compared to the other options provided. **Analysis of Incorrect Options:** * **Warfarin:** Although we monitor the **INR (International Normalized Ratio)** rather than serum drug levels, this is a form of "monitoring drug effect." In the context of NEET-PG, drugs like Warfarin and Heparin are classic examples where monitoring is mandatory due to the high risk of toxicity (bleeding). * **Phenytoin:** This is a classic candidate for TDM because it exhibits **zero-order (saturation) kinetics** at therapeutic doses. Small dose increases can lead to disproportionately large increases in plasma concentration, causing toxicity (ataxia, nystagmus). * **Gentamicin:** As an aminoglycoside, it has a narrow therapeutic window and is nephrotoxic and ototoxic. TDM (measuring peak and trough levels) is essential to ensure efficacy and prevent renal damage. **High-Yield NEET-PG Pearls:** * **Mnemonic for TDM drugs:** "**L**evels **C**an **D**etermine **P**harmacological **T**oxicity" (**L**ithium, **C**yclosporine/Digoxin, **D**igoxin, **P**henytoin/Phenobarbitone, **T**heophylline/Tricyclic Antidepressants). * **TDM is NOT required if:** The drug has a wide therapeutic index (e.g., Penicillin) or an easily measurable effect (e.g., blood pressure for Antihypertensives, blood sugar for Insulin). * **Sample Timing:** For most drugs, TDM is performed at **steady state** (usually after 4-5 half-lives).

Question 140: Which of the following inhibits CYP-P450?

A. Grapefruit juice (Correct Answer)
B. Ethanol
C. Rifampicin
D. Procainamide

Explanation: **Explanation:** The correct answer is **Grapefruit juice**. **1. Why Grapefruit juice is correct:** Grapefruit juice contains compounds called **furanocoumarins** (e.g., bergamottin), which are potent **inhibitors** of the **CYP3A4** enzyme, primarily in the intestinal wall. By inhibiting this enzyme, grapefruit juice reduces the first-pass metabolism of many drugs, leading to increased plasma concentrations and potential toxicity. Common drugs affected include statins (Atorvastatin), calcium channel blockers (Amlodipine), and immunosuppressants (Cyclosporine). **2. Why the other options are incorrect:** * **Ethanol:** Chronic alcohol consumption is a well-known **enzyme inducer** (specifically CYP2E1). However, acute large doses can act as an inhibitor. In the context of standard pharmacology exams, ethanol is typically categorized as an inducer. * **Rifampicin:** This is one of the most potent **broad-spectrum enzyme inducers**. It increases the synthesis of multiple CYP enzymes (CYP3A4, 2C9, 2C19), leading to decreased efficacy of drugs like oral contraceptives and warfarin. * **Procainamide:** This is a Class 1A antiarrhythmic drug. It is metabolized via **acetylation** (by the NAT2 enzyme), not primarily through the CYP-P450 system, and it does not act as a significant inducer or inhibitor. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Enzyme Inhibitors (VITAMIN K):** **V**alproate, **I**soniazid, **T**ame (Cimetidine), **A**miodarone, **M**acrolides (except Azithromycin), **I**ndinavir, **N**on-DHP CCBs (Verapamil/Diltiazem), **K**etoconazole (and Grapefruit juice). * **Mnemonic for Enzyme Inducers (GPRS Cell Phone):** **G**riseofulvin, **P**henytoin, **R**ifampicin, **S**moking, **C**arbamazepine, **P**henobarbitone. * **Note:** Erythromycin inhibits CYP enzymes, but **Azithromycin** does not, making it a safer choice to avoid drug interactions.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free